This company has been acquired
Inhibrx (INBX) Stock Overview
A clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
INBX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Inhibrx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.11 |
| 52 Week High | US$39.79 |
| 52 Week Low | US$14.31 |
| Beta | 2.88 |
| 1 Month Change | -0.55% |
| 3 Month Change | -6.42% |
| 1 Year Change | 38.66% |
| 3 Year Change | 55.97% |
| 5 Year Change | n/a |
| Change since IPO | 65.34% |
Recent News & Updates
Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
Summary Inhibrx Biosciences, Inc. has surged nearly 40% amid rumors of Big Pharma interest in joint spinoffs of INBRX-106 and possibly a second asset. Ozekibart’s Phase 2 data in chondrosarcoma showed a 52% risk reduction in progression or death, positioning INBX as a first-mover in an unmet oncology market. INBRX-106, in combination with Keytruda, is advancing through Phase 2/3 trials, with key data readouts and potential spinoff partnerships as near-term catalysts. Despite strong upside potential and a $300 price target from Stifel, INBX financing remains a risk, with upcoming BLA submissions and pivotal data as critical inflection points. Read the full article on Seeking AlphaInhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform
Summary INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing promising early results but faces market skepticism due to past failures of similar molecules. Financially, INBX is well-funded with over $200 million in cash and last reported income of $2 billion, providing a potential cash runway through 2025. Given the promising pipeline and strong financial position, I am tentatively optimistic about INBX and recommend a "Buy" rating. Read the full article on Seeking AlphaInhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Summary Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types. The global solid tumor therapeutics market is expected to reach $885.44 billion by 2033. Read the full article on Seeking AlphaRecent updates
Shareholder Returns
| INBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.09% | -0.9% | -2.4% |
| 1Y | 38.7% | 25.7% | 21.5% |
Return vs Industry: INBX exceeded the US Biotechs industry which returned 4.6% over the past year.
Return vs Market: INBX exceeded the US Market which returned 25.2% over the past year.
Price Volatility
| INBX volatility | |
|---|---|
| INBX Average Weekly Movement | 1.4% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INBX has not had significant price volatility in the past 3 months.
Volatility Over Time: INBX's weekly volatility has decreased from 8% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 169 | Mark Lappe | inhibrx.com |
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.
Inhibrx, Inc. Fundamentals Summary
| INBX fundamental statistics | |
|---|---|
| Market cap | US$1.79b |
| Earnings (TTM) | -US$271.15m |
| Revenue (TTM) | US$1.78m |
Is INBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INBX income statement (TTM) | |
|---|---|
| Revenue | US$1.78m |
| Cost of Revenue | US$218.11m |
| Gross Profit | -US$216.32m |
| Other Expenses | US$54.83m |
| Earnings | -US$271.15m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.17 |
| Gross Margin | -12,132.47% |
| Net Profit Margin | -15,207.80% |
| Debt/Equity Ratio | 1,799.9% |
How did INBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/31 05:17 |
| End of Day Share Price | 2024/05/29 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inhibrx, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Reni Benjamin | Citizens JMP Securities, LLC |
| Joshua Schimmer | Evercore ISI |